Overview
T2DM Management in Primary Care Practice: Addressing the Weight of it All
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This expert-led activity offers a “how to” method for introducing strategies that support management of both dysglycemia and obesity. This activity highlights the ramifications of untreated obesity in patients with dysglycemia to underscore the importance of early obesity intervention. It also outlines ways to individualize obesity and dysglycemia management, recognize the benefits of earlier treatment intensification and weight loss, understand the latest data with incretin-based therapies, and optimize strategies to achieve sustained weight loss in patients with T2DM.
Prior to participating in the activity, we recommend accessing the Clinical Inertia Assessment Tool to assess your ability to manage patients with dysglycemia and obesity.
This activity is intended for primary care physicians and advance practice providers in the primary care setting who treat patients with T2DM.
This activity outlines strategies to better ensure that patients with dysglycemia and obesity receive timely interventions and that providers overcome clinical inertia related to treatment intensification. The activity outlines the benefits of targeting both dysglycemia and weight loss, the most recent evidence with incretin-based therapy in T2DM and obesity, as well as case studies to help apply the latest recommendations and data into practice.
Upon completion of this activity, participants will be able to:
• Introduce individualized management strategies to reduce long-term complications in patients with T2DM
• Describe the benefits of earlier treatment intensification and weight loss in achieving established goals for glycemic control
• Describe the latest research on the role of incretin-based therapies in patients with T2DM, obesity, and obesity-related comorbidities
• Optimize strategies to achieve sustained weight loss in patients with T2DM based on varied patient characteristics and targets
• Introduce individualized management strategies to reduce long-term complications in patients with T2DM
• Describe the benefits of earlier treatment intensification and weight loss in achieving established goals for glycemic control
• Describe the latest research on the role of incretin-based therapies in patients with T2DM, obesity, and obesity-related comorbidities
• Optimize strategies to achieve sustained weight loss in patients with T2DM based on varied patient characteristics and targets
This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an educational grant from Lilly.
Robert Kushner, MD
Professor of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Director, Center for Lifestyle Medicine
Northwestern Medicine
Chicago, IL
Professor of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Director, Center for Lifestyle Medicine
Northwestern Medicine
Chicago, IL
Donna Ryan, MD
Professor Emerita
Pennington Biomedical
Baton Rouge, LA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Robert Kushner, MD
Advisory Board: Novo Nordisk, WW
Consultant (occasional): Boehringer Ingelheim, Pfizer
Research Support: Epitomee
Donna Ryan, MD
Advisory Board: Amgen, Altimmune, Calibrate, Epitomee, Lilly, Novo Nordisk, Painscript, Real Appeal, Wondr Health, Xeno Bioscience, Ysopia, Zealand
Consultant (occasional): Calibrate, Epitomee, IFA Celtic, Novo Nordisk, Rhythm, Ro, Scientific Intake
Consultant (retained): Wondr Health
Speaker Bureau: Novo Nordisk
Stock Shareholder (excluding mutual funds): Calibrate, Epitomee, Ro, Scientific Intake
Honorarium (Non-CME): IFA Celtic
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational tirzepatide and cagrilintide
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
